IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer
Eric Faulkner, currently Sr. Vice President, CMC, appointed…
Futura Medical – Jeff Needham to succeed John Clarke as Non-Executive Chairman of Futura Medical plc
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a…
Leucid Bio Appoints Filippo Petti as Chief Executive Officer
London, UK – 18 July 2023 – Leucid Bio (“Leucid” or the…
Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference
Professor Gertsch identifies novel transport mechanism and…
Futura Medical Announces Agreement With Haleon To Commercialise MED3000 In The USA
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a…
Vicore announces the appointment of Ahmed Mousa as CEO
Stockholm, July 13, 2023 – Vicore Pharma Holding AB (publ)…
Neuraxpharm expands outside Europe into Brazil and Mexico
Recently acquired Sanofi portfolio products to be combined with…
Versameb Strengthens its Board of Directors
Significant appointments of experienced drug development…
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
US study seeking to confirm strong efficacy data reported…
Destiny Pharma plc – Positive findings from recent SAB meeting
Confirms proposed Phase 3 development pathway and identifies…
Sequana Medical – 1,000th alfapump® implant completed
Extensive real world alfapump experience derisks planned…
Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
Exclusive license agreement for an oncological target antibody…
Biocomposites invests in Renovos Biologics – developers of the RENOVITE® nanoclay therapeutic delivery platform
RENOVITE ® nanoclay is a novel therapeutic delivery platform…
DelSiTech Announces Positive Topline Clinical Data From Phase 1 Trial With Its Sustained Release Eye Drop Platform
Turku, Finland – 29th June 2023: Drug delivery and development…
Destiny Pharma plc – Business Update
Continued progress on XF-73 partnering discussions
Susan Koppy…
Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million
Significant support from investors including the European…
Poolbeg Pharma plc – Successful Artificial Intelligence led programme identifies multiple influenza drug targets
AI analysis of unique human challenge trial data provides unparalleled…
MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults
Full enrolment and dosing commenced with its novel, prophylactic…
Astraveus raises €16.5 Million Series Seed round to advance the development of its automated, microfluidic Cell and Gene Therapy manufacturing platform
Company emerges from stealth with financing led by AdBio…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York